Viking Therapeutics (NASDAQ: VKTX) recently experienced a significant surge in its stock price, it closed on Friday Feb 16th at $36.20 up 70.27% in the last month alone.  Viking Therapeutics is developing a dual GLP-1/GIP agonist drug candidate for the treatment of metabolic disorders such as obesity. 

Result from a Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 is expected in 1Q24.

Result for Phase 1 Trial of Oral VK2735 is also expected in 1Q24.

The stock has run up in anticipation of the above clinical data.  If the data are positive, there will be renewed interest for potential takeover.

The company is also in phase 2b VOYAGE study for the treatment of NASH and Fibrosis.  Results are expected in 1H24.